Brokerages Set Alector, Inc. (NASDAQ:ALEC) PT at $3.63

Shares of Alector, Inc. (NASDAQ:ALEC) have been assigned a consensus recommendation of “Hold” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $3.6250.

A number of equities research analysts have commented on ALEC shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Alector in a report on Monday, May 4th. Cantor Fitzgerald raised shares of Alector from a “neutral” rating to an “overweight” rating in a report on Wednesday, April 15th. Wall Street Zen raised shares of Alector from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley reissued an “underweight” rating and set a $2.00 price objective on shares of Alector in a report on Monday, May 4th. Finally, BTIG Research upgraded shares of Alector from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Tuesday, March 10th.

Insider Buying and Selling at Alector

In other news, CFO Neil Lindsay Berkley sold 19,360 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total transaction of $38,139.20. Following the completion of the sale, the chief financial officer owned 379,900 shares in the company, valued at $748,403. The trade was a 4.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Arnon Rosenthal sold 87,216 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total value of $171,815.52. Following the transaction, the chief executive officer directly owned 2,367,206 shares in the company, valued at $4,663,395.82. This trade represents a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 117,580 shares of company stock valued at $232,557 over the last three months. Insiders own 8.30% of the company’s stock.

Institutional Trading of Alector

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bronte Capital Management Pty Ltd. bought a new position in shares of Alector in the 4th quarter valued at about $30,000. Hershey Trust Co. grew its position in shares of Alector by 100.0% during the 4th quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock worth $32,000 after buying an additional 10,286 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Alector during the 2nd quarter worth approximately $30,000. Virtu Financial LLC acquired a new stake in shares of Alector during the 4th quarter worth approximately $34,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Alector during the 4th quarter worth approximately $40,000. 85.83% of the stock is owned by institutional investors.

Alector Price Performance

Shares of NASDAQ ALEC opened at $1.86 on Wednesday. The stock has a market cap of $206.52 million, a PE ratio of -1.56 and a beta of 0.61. The business has a fifty day moving average of $2.07 and a two-hundred day moving average of $1.99. Alector has a 52-week low of $1.09 and a 52-week high of $3.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.25 and a current ratio of 5.25.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. Alector had a negative return on equity of 295.17% and a negative net margin of 680.83%.The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $9.67 million. As a group, equities research analysts expect that Alector will post -0.86 earnings per share for the current fiscal year.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.